{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:33:32Z","timestamp":1789518812079,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Surg"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the benefit of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of endometrial peritoneal carcinomatosis compared to CRS alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective multicentre study of patients from experienced centres in treating peritoneal malignancies from 2002 to 2015. Patients who underwent surgery for peritoneal evolution of endometrial cancer (EC) were included. Two groups of 30 women were matched and compared: \u201cCRS\u2009+\u2009HIPEC\u201d which used HIPEC after CRS, and \u201cCRS only\u201d which did not use HIPEC. We analysed clinical, pathologic and treatment data for patients with peritoneal metastases from EC. The outcome measures were morbidity, overall survival (OS), and progression-free survival (PFS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In \u201cCRS plus HIPEC\u201d group, 96.7% of women were treated for recurrence, while in \u201cCRS only\u201d 83.3 were treated for primary disease. There was no significant difference between Peritoneal Carcinomatosis Index at laparotomy or Completeness of Cytoreduction score. Grade III and IV complications rates did not significantly differ between \u201cCRS plus HIPEC\u201d group and \u201cCRS only\u201d group (20.7% vs 20.7%, p\u2009=\u20090.739). Survival analysis showed no statistical difference between both groups. Median OS time was 19.2\u00a0months in \u201cCRS plus HIPEC\u201d group and 29.7\u00a0months in \u201cCRS only\u201d group (p\u2009=\u20090.606). Median PFS survival time was 10.7\u00a0months in \u201cCRS plus HIPEC\u201d group and 13.1\u00a0months in \u201cCRS only\u201d group (p\u2009=\u20090.511).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The use of HIPEC combined to CRS did not have any significance as regard the DFS and OS over CRS alone in patients with primary or recurrent peritoneal metastasis of endometrial cancer.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12893-021-01449-z","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T20:02:28Z","timestamp":1641585748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups"],"prefix":"10.1186","volume":"22","author":[{"given":"Manuel","family":"Gomes David","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoual","family":"Bakrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Salleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Christine","family":"Kaminsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marc","family":"Bereder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Jacques","family":"Tuech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuno","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"issue":"1","key":"1449_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin f\u00e9vr. 2016;66(1):7\u201330.","journal-title":"CA Cancer J Clin f\u00e9vr"},{"issue":"1","key":"1449_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/annonc\/mdv484","volume":"27","author":"N Colombo","year":"2016","unstructured":"Colombo N, Creutzberg C, Amant F, Bosse T, Gonz\u00e1lez-Mart\u00edn A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16\u201341.","journal-title":"Ann Oncol"},{"issue":"2","key":"1449_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/COC.0b013e31829a2974","volume":"38","author":"LS Bradford","year":"2015","unstructured":"Bradford LS, Rauh-Hain JA, Schorge J, Birrer MJ, Dizon DS. Advances in the management of recurrent endometrial cancer. Am J Clin Oncol. 2015;38(2):206\u201312.","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"1449_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/IGC.0b013e3181a83f7e","volume":"20","author":"N Bakrin","year":"2010","unstructured":"Bakrin N, Cotte E, Sayag-Beaujard A, Raudrant D, Isaac S, Mohamed F, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of recurrent endometrial carcinoma confined to the peritoneal cavity. Int J Gynecol Cancer. 2010;20(5):809\u201314.","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl 1","key":"1449_CR5","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/S0020-7292(06)60031-3","volume":"95","author":"WT Creasman","year":"2006","unstructured":"Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S105-143.","journal-title":"Int J Gynaecol Obstet"},{"issue":"9","key":"1449_CR6","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1097\/IGC.0000000000000543","volume":"25","author":"T Turan","year":"2015","unstructured":"Turan T, Tasci T, Karalok A, Ureyen I, Kocak O, Turkmen O, et al. Salvage cytoreductive surgery for recurrent endometrial cancer. Int J Gynecol Cancer. 2015;25(9):1623\u201332.","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"1449_CR7","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.3802\/jgo.2017.28.e48","volume":"28","author":"MC Lim","year":"2017","unstructured":"Lim MC, Yoo HJ, Song YJ, Seo S-S, Kang S, Kim SH, et al. Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer. J Gynecol Oncol. 2017;28(4):e48.","journal-title":"J Gynecol Oncol"},{"key":"1449_CR8","doi-asserted-by":"crossref","unstructured":"Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. Oxford Academic. https:\/\/academic.oup.com\/annonc\/article\/18\/5\/827\/217876\/. Accessed 4 Oct 2019.","DOI":"10.1093\/annonc\/mdl428"},{"issue":"5","key":"1449_CR9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1080\/02656736.2017.1301576","volume":"33","author":"D Go\u00e9r\u00e9","year":"2017","unstructured":"Go\u00e9r\u00e9 D, Passot G, Gelli M, Levine EA, Bartlett DL, Sugarbaker PH, et al. Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI). Int J Hyperth. 2017;33(5):520\u20137.","journal-title":"Int J Hyperth"},{"issue":"4","key":"1449_CR10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/IGC.0000000000000664","volume":"26","author":"A Hotouras","year":"2016","unstructured":"Hotouras A, Desai D, Bhan C, Murphy J, Lampe B, Sugarbaker PH. Heated IntraPEritoneal Chemotherapy (HIPEC) for patients with recurrent ovarian cancer: a systematic literature review. Int J Gynecol Cancer. 2016;26(4):661\u201370.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"1449_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.suronc.2018.05.006","volume":"27","author":"GS Kireeva","year":"2018","unstructured":"Kireeva GS, Gafton GI, Guseynov KD, Senchik KY, Belyaeva OA, Bespalov VG, et al. HIPEC in patients with primary advanced ovarian cancer: is there a role? A systematic review of short- and long-term outcomes. Surg Oncol. 2018;27(2):251\u20138.","journal-title":"Surg Oncol"},{"key":"1449_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jviscsurg.2015.11.010","volume":"153","author":"C Honor\u00e9","year":"2016","unstructured":"Honor\u00e9 C, Go\u00e9r\u00e9 D, Macovei R, Colace L, Benhaim L, Elias D. Peritoneal carcinomatosis from unusual cancer origins: is there a role for hyperthermic intraperitoneal chemotherapy? J Visc Surg. 2016;153:101\u20137.","journal-title":"J Visc Surg"},{"issue":"3","key":"1449_CR13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1245\/s10434-017-6307-3","volume":"25","author":"T Cornali","year":"2018","unstructured":"Cornali T, Sammartino P, Kopanakis N, Christopoulou A, Framarino Dei Malatesta M, Efstathiou E, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for patients with peritoneal metastases from endometrial cancer. Ann Surg Oncol. 2018;25(3):679\u201387.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1449_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5144\/0256-4947.2014.159","volume":"34","author":"A Abu-Zaid","year":"2014","unstructured":"Abu-Zaid A, Azzam AZ, AlOmar O, Salem H, Amin T, Al-Badawi IA. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for managing peritoneal carcinomatosis from endometrial carcinoma: a single-center experience of 6 cases. Ann Saudi Med. 2014;34(2):159\u201366.","journal-title":"Ann Saudi Med"},{"key":"1449_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejogrb.2013.10.026","volume":"172","author":"J Delotte","year":"2014","unstructured":"Delotte J, Desantis M, Frigenza M, Quaranta D, Bongain A, Benchimol D, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of endometrial cancer with peritoneal carcinomatosis. Eur J Obstet Gynecol Reprod Biol. 2014;172:111\u20134.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"1449_CR16","first-page":"1041","volume":"33","author":"DA Santeufemia","year":"2013","unstructured":"Santeufemia DA, Lumachi F, Basso SMM, Tumolo S, Re GL, Capobianco G, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy as salvage treatment for a late wound recurrence of endometrial cancer. Anticancer Res. 2013;33(3):1041\u20134.","journal-title":"Anticancer Res"},{"issue":"1","key":"1449_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1525-1438.2006.00751.x","volume":"17","author":"CW Helm","year":"2007","unstructured":"Helm CW, Toler CR, Martin RS, Gordinier ME, Parker LP, Metzinger DS, et al. Cytoreduction and intraperitoneal heated chemotherapy for the treatment of endometrial carcinoma recurrent within the peritoneal cavity. Int J Gynecol Cancer. 2007;17(1):204\u20139.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"1449_CR18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","volume":"39","author":"PR Rosenbaum","year":"1985","unstructured":"Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39(1):33\u20138.","journal-title":"Am Stat"},{"issue":"2","key":"1449_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/00000658-199502000-00002","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221(2):124\u201332.","journal-title":"Ann Surg"},{"issue":"4","key":"1449_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/jso.21061","volume":"98","author":"O Glehen","year":"2008","unstructured":"Glehen O, Cotte E, Kusamura S, Deraco M, Baratti D, Passot G, et al. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol. 2008;98(4):242\u20136.","journal-title":"J Surg Oncol"},{"issue":"3","key":"1449_CR21","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","volume":"92","author":"HM Keys","year":"2004","unstructured":"Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744\u201351.","journal-title":"Gynecol Oncol"},{"issue":"9213","key":"1449_CR22","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","volume":"355","author":"CL Creutzberg","year":"2000","unstructured":"Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, W\u00e1rl\u00e1m-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet Lond Engl. 2000;355(9213):1404\u201311.","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"1449_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.crad.2006.06.015","volume":"62","author":"SA Sohaib","year":"2007","unstructured":"Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol. 2007;62(1):28\u201334 (discussion 35-36).","journal-title":"Clin Radiol"},{"issue":"4","key":"1449_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10585-019-09970-5","volume":"36","author":"CB Tempfer","year":"2019","unstructured":"Tempfer CB, Kern P, Dogan A, Hilal Z, Rezniczek GA. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for endometrial cancer-derived peritoneal metastases: a systematic review. Clin Exp Metastasis. 2019;36(4):321\u20139.","journal-title":"Clin Exp Metastasis"},{"issue":"19","key":"1449_CR25","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1200\/JCO.2004.02.088","volume":"22","author":"JT Thigpen","year":"2004","unstructured":"Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22(19):3902\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1449_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/annonc\/mdg112","volume":"14","author":"FH van Wijk","year":"2003","unstructured":"van Wijk FH, Aapro MS, Bolis G, Chevallier B, van der Burg MEL, Poveda A, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol. 2003;14(3):441\u20138.","journal-title":"Ann Oncol"},{"issue":"8","key":"1449_CR27","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/annonc\/mdh316","volume":"15","author":"GF Fleming","year":"2004","unstructured":"Fleming GF, Filiaci VL, Bentley RC, Herzog T, Sorosky J, Vaccarello L, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol. 2004;15(8):1173\u20138.","journal-title":"Ann Oncol"},{"issue":"10","key":"1449_CR28","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO;2-Z","volume":"89","author":"BA Goff","year":"2000","unstructured":"Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89(10):2068\u201375.","journal-title":"Cancer"},{"issue":"1","key":"1449_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ygyno.2010.04.005","volume":"118","author":"JN Barlin","year":"2010","unstructured":"Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol. 2010;118(1):14\u20138.","journal-title":"Gynecol Oncol"},{"key":"1449_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.suronc.2019.12.002","volume":"33","author":"\u00c1 Navarro-Barrios","year":"2020","unstructured":"Navarro-Barrios \u00c1, Gil-Mart\u00ednez J, Ramos-Bernardo I, Barrios P, Mu\u00f1oz-Casares C, Torres-Melero J, et al. Intraperitoneal hyperthermic chemotherapy after cytoreduction in patients with peritoneal metastases from endometrial cancer. The next frontier? Surg Oncol. 2020;33:19\u201323.","journal-title":"Surg Oncol"},{"issue":"9","key":"1449_CR31","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/14737140.2018.1491311","volume":"18","author":"EV Connor","year":"2018","unstructured":"Connor EV, Rose PG. Management strategies for recurrent endometrial cancer. Expert Rev Anticancer Ther. 2018;18(9):873\u201385.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1449_CR32","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1245\/s10434-020-08812-z","volume":"28","author":"A Gaudet Chardonnet","year":"2020","unstructured":"Gaudet Chardonnet A, Aza\u00efs H, Ballester M, Raimond E, Bendifallah S, Ouldamer L, et al. Prognostic value and risk factors of peritoneal carcinomatosis recurrence for patients with endometrial cancer: a multicenter study from the FRANCOGYN Group. Ann Surg Oncol. 2020;28:212\u201321.","journal-title":"Ann Surg Oncol"}],"container-title":["BMC Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-021-01449-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12893-021-01449-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-021-01449-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T21:57:31Z","timestamp":1726437451000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsurg.biomedcentral.com\/articles\/10.1186\/s12893-021-01449-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1449"],"URL":"https:\/\/doi.org\/10.1186\/s12893-021-01449-z","relation":{},"ISSN":["1471-2482"],"issn-type":[{"value":"1471-2482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]},"assertion":[{"value":"11 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was performed in accordance with the Declaration of Helsinki and was approved by an appropriate ethics committee. The French National Data Protection Authority approved this study: Commission Nationale de l'Informatique et des Libert\u00e9s de France\u2014INDS n\u00b0 1510270220).A written consent has been obtained for all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}